OFEV®
Overview
Product overview
OFEV® is a multi-targeted tyrosine kinase inhibitor that binds competitively to the kinases and blocks the intracellular signaling cascades, which have been demonstrated to be involved in the pathogenesis of fibrotic tissue remodeling in interstitial lung diseases.
Product Key Facts
Indications
Idiopathic pulmonary fibrosis (IPF)
To slow the decline in lung function in people with systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Progressive fibrosing interstitial lung disease (PF-ILDs)
Active ingredient
Nintedanib
Legal category
Prescription only medicine
Dosage
100 milligrams per capsule
150 milligrams per capsule
Administration form
Oral capsules
Dosage form
Soft capsules
Pack sizes
One box contains 60 soft
capsules in blisters
Reference
-
OFEV® Soft Capsules approved package insert. USPI March 20202+HA request. Approved 07/2020.
![[BI-Medical] 心衰竭病人的腎功能惡化： 停藥或調整？](/tw/sites/default/files/2023-05/33_SC-TW-00276.png "[BI-Medical] 心衰竭病人的腎功能惡化： 停藥或調整？")
![[BI-Medical] 心衰竭病人的腎功能惡化： 停藥或調整？](/tw/sites/default/files/styles/bi_gds_medium/public/2023-02/arrow.png "[BI-Medical] 心衰竭病人的腎功能惡化： 停藥或調整？"){kind=icon}
![[BI Medical] 糖尿病前期病人與他們的心血管風險](/tw/sites/default/files/2023-02/24.%20SC-TW-00284.png "[BI Medical] 糖尿病前期病人與他們的心血管風險")
